Why the study?
Ventricular arrhythmias remain a recognized complication of traditional and novel cancer therapies, but their underlying mechanisms are poorly understood.
This review summarizes the mechanisms, identification, prevention, and management of ventricular arrhythmias induced by cancer therapies.
Answers are grounded in this paper and cite their sources.
Raises clinician awareness of cancer therapy-induced ventricular arrhythmias; leaves open the need for prospective trials on prevention and management.
Cardiovascular disease and cancer are the leading causes of morbidity and mortality in the US. Despite the significant progress made in cancer treatment leading to improved prognosis and survival, ventricular arrhythmias (VA) remain a known cardiovascular complication either exacerbated or induced by the direct and indirect effects of both traditional and novel cancer treatments. Although interruption of cancer treatment because of VA is rarely required, knowledge surrounding this issue is essential for optimising the overall care of patients with cancer. The mechanisms of cancer-therapeutic-induced VA are poorly understood. This review will discuss the ventricular conduction (QRS) and repolarisation abnormalities (QTc prolongation), and VAs associated with cancer therapies, as well as existing strategies for the identification, prevention and management of cancer-treatment-induced VAs.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: